At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 45 enrolled
Drug / intervention
Benralizumabcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BURAN: Effects of Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging Parameters
In Brief
A Phase 4 clinical trial evaluating Benralizumab for Asthma. Completed, enrolled 45 participants across 25 sites in 7 countries.
Detailed Summary
This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional Respiratory Imaging (FRI) platform.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesAustralia, Belgium, France, Portugal, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartOct 2022
Primary CompletionJul 2024
TodayJul 2026
First PostedSep 23, 2022
Enrollment StartOct 11, 2022
Primary CompletionJul 19, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 3.8 years ago
Interventions
Benralizumabcombination
Participants will receive benralizumab subcutaneously.